Curriculum vitae Prof. Dr. med. Karl Broich
Academic education
- Study of Human Medicine at the Medical Faculty of the Rheinische Friedrich-Wilhelms-Universität Bonn, 1979 – 1985
- Specialist training (neurology, psychotherapy) at the Clinics of Neurology and Psychiatry of the Medical Faculty of the Rheinische Friedrich-Wilhelms-Universität Bonn, 1985 - 1993
- Lecturer and Supervisor for cognitive behavioral therapy since 2002
- Honorary Professor at the Medical Faculty of the Rheinische Friedrich-Wilhelms-Universität Bonn
Positions at BfArM
| since 2014 | President of the Federal Institute for Drugs and Medical Devices (BfArM) |
| 2009 - 2014 | Vice President of the Federal Institute for Drugs and Medical Devices (BfArM) |
| 2000 - 2009 | Management positions at the Federal Institute for Drugs and Medical Devices (BfArM) |
| 1990 – 1991 | Research stay at the Hospital of the University of Pennsylvania, Philadelphia, USA (PET and SPECT imaging of neurotransmitter receptors in neurodegenerative diseases) |
| 1985 – 2000 | Clinical-academic activity at neurological and psychiatric University Hospitals |
Current activities in the European network of regulatory authorities
Member of the Management Board of the European Medicines Agency (EMA Management Board), Member of the HMA Management Group. He is also co-chair of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), the Darwin EU Advisory Board and the Network Data Steering Group (NDSG) of the EMA.
Publications / other activities
Member of numerous societies, such as the German Society for Psychiatry, Psychotherapy and Neurology (DGPPN), German Society for Regulatory Affairs (DGRA), German Society for Integrated Care in the Healthcare System (DGIV).
Prof. Dr. Broich is author and co-author of over 250 essays (original scientific papers, reviews, book contributions). Some of them are available at PubMed (National Library of Medicine) under the following link: Publications
Scientific focus
His scientific focus is on clinical psychopharmacology, neurodegenerative disorders and the potential of biomarkers, and clinical trial methodology, among others.